- Home
- RCKT vs MREO Comparison
RCKT vs MREO Comparison
Compare RCKT & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCKT
- MREO
- Stock Information
- Founded
- RCKT 1999
- MREO 2015
- Country
- RCKT United States
- MREO United Kingdom
- Employees
- RCKT N/A
- MREO N/A
- Industry
- RCKT Biotechnology: Pharmaceutical Preparations
- MREO Biotechnology: Pharmaceutical Preparations
- Sector
- RCKT Health Care
- MREO Health Care
- Exchange
- RCKT Nasdaq
- MREO Nasdaq
- Market Cap
- RCKT 328.6M
- MREO 281.6M
- IPO Year
- RCKT N/A
- MREO N/A
- Fundamental
- Price
- RCKT $3.19
- MREO $1.76
- Analyst Decision
- RCKT Buy
- MREO Strong Buy
- Analyst Count
- RCKT 13
- MREO 5
- Target Price
- RCKT $12.96
- MREO $7.40
- AVG Volume (30 Days)
- RCKT 5.7M
- MREO 932.9K
- Earning Date
- RCKT 11-06-2025
- MREO 11-11-2025
- Dividend Yield
- RCKT N/A
- MREO N/A
- EPS Growth
- RCKT N/A
- MREO N/A
- EPS
- RCKT N/A
- MREO N/A
- Revenue
- RCKT N/A
- MREO $500,000.00
- Revenue This Year
- RCKT N/A
- MREO N/A
- Revenue Next Year
- RCKT $108.43
- MREO $55.50
- P/E Ratio
- RCKT N/A
- MREO N/A
- Revenue Growth
- RCKT N/A
- MREO N/A
- 52 Week Low
- RCKT $2.19
- MREO $1.47
- 52 Week High
- RCKT $22.01
- MREO $4.72
- Technical
- Relative Strength Index (RSI)
- RCKT 47.80
- MREO 48.19
- Support Level
- RCKT $3.09
- MREO $1.68
- Resistance Level
- RCKT $3.29
- MREO $1.88
- Average True Range (ATR)
- RCKT 0.16
- MREO 0.07
- MACD
- RCKT -0.02
- MREO 0.01
- Stochastic Oscillator
- RCKT 14.64
- MREO 43.18
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).